NCT06452082Completed
Risk in Devel Long-COVID in Contracting SARS-CoV-2 Infection After COVID-19 Vaccination in Relation to Vitamin D3 Suppl
Retrospective Observational Study on the Risk Developing Long-COVID Syndrome After Acute COVID-19 Disease and in Contracting SARS-CoV-2 Infection After COVID-19 Vaccination in Relation to Vitamin D3 Suppl in Outpatients of Endocr Dept
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
The aim of this observational retrospective study is to evaluate the effect of supplementation with cholecalciferol D3 in reducing the risk of: * occurence of Long COVID syndrome after acute COVID-19 illness * occurence of SARS-CoV-2 infection after anti-COVID-19 vaccination
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 200 (actual)
- First submitted
- 6 Jun 2024
- Start date
- 20 Mar 2024
- Primary completion date
- 24 Jul 2025
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06452082
What you commit to
- Study type: Observational
- Participants enrolled: 200
- From 20 Mar 2024 to the primary completion date, 24 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients treated with drugs that interfere with vitamin D metabolism
- patients treated with drugs that interfere with vitamin D metabolism
Other illness
- patients suffering from primary and/or acquired immunodeficiency and/or severe impairment of general clinical conditions
- first vaccination anti Sars COVID performed before the acute infection
- first vaccination performed within 6 months of the acute infection
- patients suffering from primary and/or acquired immunodeficiency and/or severe impairment of general clinical conditions
- acute infection before the vaccination
Age
- age ≤ 18
- age ≤ 18
Other
- pregnant or breastfeeding women
- patients unable to sign the informed consent
- pregnant or breastfeeding women
- additional vaccination performed before 6-12 months
- patients unable to sign the informed consent
Who the study is looking for
- age ≥18
- outpatient with first visit on Endocrinology Department performed from 01/01/2020 to 31/12/2022
- previous SARS CoV-2 infection
- clinical,anamnestic and therapeutic data 6 months post SARS CoV-2 infection
- data on cholecalciferol supplementation
- signature of informed consent
- \-- age ≥18
- outpatient with first visit on Endocrinology Department performed from 01/01/2020 to 31/12/2022
- vaccination with BNT162b2 Biontec mRNA Pfizer/BioNtech
- clinical, anamnestic and therapeutic data 6 months post SARS CoV-2 infection
- data on cholecalciferol supplementation
- signature of informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Luigi di Filippo Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.